Five-year outcomes following early experience with transapical TMVR

Summary

In this discussion, Christopher Allen and Michael Reardon review the five-year results of an early transapical TMVR system implanted in very high-risk, inoperable patients.

The device showed sustained elimination of mitral regurgitation, with over 80% of patients maintaining trace or no MR at five years and no paravalvular leak. Clinical status improved markedly, with most patients moving from NYHA III/IV to I/II. Durability remained strong, with only one early reintervention and very low rates of moderate valve dysfunction or thrombosis. Right ventricular function and pulmonary pressures also improved, supporting the overall hemodynamic benefit. Michael Reardon highlights how these results laid the foundation for today’s less invasive transfemoral transseptal TMVR systems, which offer improved screening and reduced risk of LVOT obstruction.

EuroIntervention: Five-Year Outcomes of the Early-Generation Intrepid Transapical Transcatheter Mitral Valve Replacement System

This interview was filmed at PCR London Valves 2025: see more videos here.